Huge Honour for Dr Jehangir Cama & Team!

BioTryp Therapeutics, a University of Cambridge spin-out, has won the prestigious 2026 ELRIG Drug Discovery Innovation Award for its innovative biofilm-targeting technology. As Jehangir Cama (Co-founder and CCO) states, “Winning this award at such a prestigious drug discovery conference is a wonderful achievement for our team.”

Selected from more than 40 companies in the Breakthrough Zone at ELRIG Drug Discovery 2026, BioTryp received recognition for its innovative approach and potential to make a difference in drug discovery and development.

The BioTryp Therapeutics team include Dr Jehangir Cama (Co-founder and CCO); Dr Juliette Nourry (Research Scientist); Dr David Summers (Co-founder and CSO); Dr Ashraf Zarkan (Co-founder and CEO); and Mr Kieran Abbott (Research Scientist).

A short interview with Dr Jehangir Cama, Fellow of Clare Hall, Cambridge, whose work in the Physics of Medicine dates back to his doctoral research at Trinity College, Cambridge, conducted at the Cavendish Laboratory, University of Cambridge. His vision is to combine the spirit of Parsi entrepreneurship with cutting-edge scientific research to advance innovation for the benefit of science and humanity.

  1. What does winning the 2026 ELRIG Drug Discovery Innovation Award mean to you, both personally and professionally?

It gave us an opportunity to present our technology to a highly relevant audience and receive valuable recognition and validation for our work.

  1. What makes BioTryp’s technology different from existing treatments?

We are developing a new approach to treating bacterial infections. Some bacteria protect themselves by forming communities called biofilms, which act like a shield and make it difficult for antibiotics to reach and eliminate them. As a result, bacteria can survive treatment and cause infections to return. This is particularly challenging in recurrent urinary tract infections (UTIs), which is our first target area.

Our anti-biofilm drugs are designed to prevent these protective communities from forming. We aim to use them alongside antibiotics to improve treatment effectiveness and potentially as standalone treatments to prevent infections from recurring.

  1. Why is there a need for this new approach?

There are currently no comparable anti-biofilm treatments available in the market, and there is an urgent need for new ways to tackle bacterial infections.UTIs are extremely common, and many patients experience repeated infections.

Antibiotic resistance is becoming a major global health concern, with existing antibiotics gradually losing their effectiveness.  We aim to change this approach. So, having these sorts of new treatments would augment our arsenal of drugs to tackle these infections. We hope to combine our anti-biofilm drugs with antibiotics during treatment and then potentially use the anti-biofilms on their own to help prevent future infections.

As the company moves towards the next stages of drug development, its work highlights the importance of discovery and innovation in addressing the growing challenge of antibiotic resistance.

Congratulations to Dr Jehangir Cama and the entire BioTryp Therapeutics team on this well-deserved recognition. We wish them continued success as they take this promising technology forward.

-Freny Daruwalla

Full article published in Jam-e-Jamshed on15.11.2026

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.